Skip to main content

Obesity Or Overweight

Metabolic Diseases
3
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%
+ 5 programs with unclassified modality

Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.

$70.5B marketMature↑ Growing30 products15 companies

Key Trends

  • GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
  • SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
  • Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins

Career Verdict

Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
#2OZEMPICGrowing
$9.2B
Novo Nordisk·Peak12.4yr
#3JARDIANCEGrowing
$8.8B
#5FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

FXa Inhibitors (Anticoagulants)
$18.3B(26%)

stable, mature franchise

GLP-1 Agonists
$18.2B(26%)

rapid growth, expanding indications

SGLT2 Inhibitors
$9.4B(13%)

growing, cardio-renal expansion

Insulin Analogs
$7.8B(11%)

stable, generics pressure

DPP-4 Inhibitors
$5.4B(8%)

declining, patent cliff 2027

Career Outlook

Growing

Metabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.

Breaking In

Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.

For Experienced Professionals

Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.

In-Demand Skills

Commercial acumen and healthcare economics (GLP-1 market dynamics)Regulatory affairs (label expansion, indication creep for SGLT2/GLP-1)Digital health and CGM/insulin device experienceReal-world evidence generation and health outcomes research

Best For

Brand Manager (peak-cycle GLP-1 products)Medical Science Liaison (cardio-renal expansion)Market Access / Health Economics (SGLT2 outcomes)Commercial Operations (launch support for next-gen)

Hiring Landscape

$153K-$274K

Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.

574
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

270Growing
154Growing
42Stable
38Stable

By Department

Commercial(29%)
$220K
Engineering(22%)
$197K
Manufacturing(8%)
$274K
Clinical Operations(4%)
$153K

Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
AZD6234Phase 21 trial
AZD9550Phase 21 trial
Active Trials
NCT06595238Completed262Est. Dec 2025
NCT06862791Active Not Recruiting377Est. May 2026
Regor Therapeutics
Regor TherapeuticsChina - Shanghai
1 program
1
RGT001-075Phase 21 trial
Active Trials
NCT06867718Active Not Recruiting236Est. Dec 2025
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
Saxenda®N/A1 trial
CagrilintidePHASE_3Peptide1 trial
CagrilintidePHASE_3Peptide1 trial
Active Trials
NCT05153590Completed269Est. Apr 2022
NCT05813925Completed331Est. Mar 2025
NCT05996848Completed300Est. Feb 2025
Eccogene
EccogeneChina - Shanghai
1 program
AZD5004PHASE_11 trial
Active Trials
NCT06988553Completed45Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskCagrilintide
Novo NordiskCagrilintide
AstraZenecaAZD9550
Regor TherapeuticsRGT001-075
AstraZenecaAZD6234
EccogeneAZD5004
Novo NordiskSaxenda®

Clinical Trials (7)

Total enrollment: 1,820 patients across 7 trials

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Start: Aug 2023Est. completion: Feb 2025300 patients
Phase 3Completed

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Start: Apr 2023Est. completion: Mar 2025331 patients
Phase 3Completed

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Start: Feb 2025Est. completion: May 2026377 patients
Phase 2Active Not Recruiting

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Start: Jan 2025Est. completion: Dec 2025236 patients
Phase 2Active Not Recruiting

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Start: Oct 2024Est. completion: Dec 2025262 patients
Phase 2Completed

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

Start: Jun 2025Est. completion: Nov 202545 patients
Phase 1Completed

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Start: Dec 2021Est. completion: Apr 2022269 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.